Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at USD 269.59 USD in weekly data.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • The company's enterprise value to sales, at 3.51 times its current sales, is high.
  • The underlying tendency is negative on the weekly chart below the resistance at 356.66 USD
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
REGENERON PHARMACEUTICALS-23.20%31 388
GILEAD SCIENCES-0.06%79 166
VERTEX PHARMACEUTICALS8.73%46 313
GENMAB29.13%13 359
NEUROCRINE BIOSCIENCES, INC..36.66%8 937
BEIGENE LTD--.--%8 619
SAREPTA THERAPEUTICS INC-14.22%6 959
HUALAN BIOLOGICAL ENGINEERI..--.--%6 835
EXELIXIS, INC.1.93%6 073
BLUEBIRD BIO INC7.57%5 898
ASCENDIS PHARMA A/S79.22%5 287
TONGHUA DONGBAO PHARMACEUTI..23.31%4 923
SPARK THERAPEUTICS INC--.--%3 879
CHINA BIOLOGIC PRODUCTS HOL..28.92%3 744
BIOCON LTD-29.45%3 701
IDORSIA LTD50.55%3 305
More Results
Financials (USD)
Sales 2019 7 650 M
EBIT 2019 2 355 M
Net income 2019 2 020 M
Finance 2019 4 498 M
Yield 2019 -
P/E ratio 2019 16,2x
P/E ratio 2020 13,8x
EV / Sales2019 3,51x
EV / Sales2020 2,98x
Capitalization 31 388 M
Upcoming event on REGENERON PHARMACEUTICALS
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes